Last reviewed · How we verify
GSK Biologicals' investigational vaccine GSK2340274A
At a glance
| Generic name | GSK Biologicals' investigational vaccine GSK2340274A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age (PHASE3)
- Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) (PHASE2)
- Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults (PHASE1)
- Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years (PHASE2)
- Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1) (PHASE3)
- Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old (PHASE1)
- Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: